ALBIREO PHARMA, INC. acquired Albireo accelerating growth

ALBIREO PHARMA, INC. -> Albireo accelerating growth · $42.00

and E.U., with potential in other rare diseases · Acquisition aligned with Ipsen's long-term strategy for expanding the scope of its Rare Disease portfolio and pipeline · Ipsen to commence cash tender offer to acquire all issued and outstanding s